Using zwitterionic polyethylene glycol to improve drug delivery
Zwitterionic polyethylene glycol for therapeutic delivery
This study is looking at a special type of PEG that could help make biologic drugs and nanomedicines work better by staying in your bloodstream longer, which might lead to improved treatments for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10945772 on NIH RePORTER |
What this research studies
This research investigates the use of zwitterionic polyethylene glycol (PEG) to enhance the delivery and effectiveness of biologic drugs and nanomedicines. By attaching PEG to these therapeutics, the study aims to extend their circulation time in the bloodstream, which can lead to better treatment outcomes. The approach focuses on overcoming challenges posed by anti-PEG antibodies that can reduce the efficacy of PEGylated drugs. Patients may benefit from improved therapeutic options that are less likely to be cleared by the immune system.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who require biologic therapies or nanomedicines and may benefit from improved drug delivery methods.
Not a fit: Patients who do not require biologic drugs or nanomedicines may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and longer-lasting treatments for various conditions.
How similar studies have performed: Previous research has shown success with PEGylated therapeutics, indicating a promising avenue for further exploration.
Where this research is happening
Philadelphia, United States
- Drexel University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cheng, Hao — Drexel University
- Study coordinator: Cheng, Hao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.